| __timestamp | Intra-Cellular Therapies, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 10337679 | 15746000 |
| Thursday, January 1, 2015 | 18187286 | 13392000 |
| Friday, January 1, 2016 | 24758063 | 9290000 |
| Sunday, January 1, 2017 | 23666957 | 7672000 |
| Monday, January 1, 2018 | 30099855 | 15293000 |
| Tuesday, January 1, 2019 | 64947625 | 22648000 |
| Wednesday, January 1, 2020 | 186363444 | 21864000 |
| Friday, January 1, 2021 | 272611040 | 37318000 |
| Saturday, January 1, 2022 | 358782000 | 48130000 |
| Sunday, January 1, 2023 | 409864000 | 108146000 |
Unlocking the unknown
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Intra-Cellular Therapies, Inc. and Madrigal Pharmaceuticals, Inc. have showcased contrasting strategies in this domain. From 2014 to 2023, Intra-Cellular Therapies saw a staggering 3,860% increase in SG&A expenses, peaking in 2023. This reflects their aggressive expansion and investment in operational infrastructure. In contrast, Madrigal Pharmaceuticals maintained a more conservative growth, with a 587% rise over the same period, indicating a focus on lean operations. The year 2023 marked a significant divergence, with Intra-Cellular's expenses nearly four times higher than Madrigal's. This analysis highlights the strategic choices companies make in balancing growth and efficiency, offering valuable insights for investors and industry analysts alike.
Operational Costs Compared: SG&A Analysis of GSK plc and Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?